Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FATE-NK100 + IL-2 in Recurrent Ovarian Cancer
NCT03213964Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Oct 2017
- Primary completion
- Mar 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FATE-NK100 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Oct 2017; status: completed.
02
Drugs
FATE-NK100
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03213964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213964.